A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
David R WiseRussell K PachynskiSamuel R DenmeadeRahul R AggarwalJiehui DengVictor Adorno FeblesArjun V BalarMinas P EconomidesCynthia LoomisShanmugapriya SelvarajMichael HaasMichael H KageyWalter NewmanJason BaumAndrea B TroxelSarah GriglunDayna LeisNina YangViktoriya AranchiySabrina MachadoErika WaalkesGabrielle GarganoNadia SoamchandAmrutesh PuranikPratip ChattopadhyayEzeddin FedalFang-Ming DengQinghu RenLuis ChiribogaJonathan MelamedCynthia A SirardKwok-Kin WongPublished in: Prostate cancer and prostatic diseases (2024)
DKN-01 600 mg was well tolerated. DKK1 blockade has modest anti-tumor activity as a monotherapy for mCRPC. Anti-tumor activity was observed in the combination cohorts, but the response duration was limited. DKK1 expression in the majority of mCRPC is low and did not clearly correlate with anti-tumor activity of DKN-01 plus docetaxel.